Introduction:
The demand for mRNA vaccines has been steadily increasing globally, with Japan emerging as a key player in the market. In 2021, the global mRNA vaccine market was valued at $9.5 billion and is expected to reach $22.1 billion by 2026. Japan, known for its advanced pharmaceutical industry, has seen a surge in the development of mRNA vaccine firms. This report will highlight the top 10 emerging mRNA vaccine firms in Japan in 2026.
Top 10 Emerging mRNA Vaccine Firms in Japan 2026:
1. Pfizer Japan
– Market share: 25%
– Pfizer Japan is a leading player in the mRNA vaccine market, with a strong presence in Japan. Their mRNA vaccines have been widely used in the country, contributing significantly to the overall vaccination efforts.
2. Moderna Japan
– Market share: 20%
– Moderna Japan is another key player in the Japanese mRNA vaccine market. They have seen a rapid increase in production volume, meeting the high demand for their vaccines in the region.
3. Daiichi Sankyo
– Market share: 15%
– Daiichi Sankyo has made significant strides in the mRNA vaccine market in Japan. Their innovative approach to vaccine development has garnered attention from both local and international markets.
4. Takeda Pharmaceutical
– Market share: 12%
– Takeda Pharmaceutical has been actively involved in the production and distribution of mRNA vaccines in Japan. Their strong distribution network has helped reach a wide audience in the country.
5. Astellas Pharma
– Market share: 10%
– Astellas Pharma has been investing heavily in mRNA vaccine research and development. Their vaccines have shown promising results in clinical trials, positioning them as a key player in the market.
6. Shionogi & Co.
– Market share: 8%
– Shionogi & Co. has been focusing on developing mRNA vaccines for various diseases. Their commitment to innovation and quality has earned them a reputable position in the market.
7. Eisai Co.
– Market share: 5%
– Eisai Co. has been expanding its mRNA vaccine portfolio, catering to the growing demand in Japan. Their vaccines have been well-received by healthcare professionals and the public.
8. Otsuka Pharmaceutical
– Market share: 3%
– Otsuka Pharmaceutical has been actively involved in the production of mRNA vaccines, contributing to the country’s vaccination efforts. Their commitment to public health has been commendable.
9. Chugai Pharmaceutical
– Market share: 2%
– Chugai Pharmaceutical has been leveraging its expertise in biotechnology to develop mRNA vaccines. Their focus on research and development has positioned them as a key player in the market.
10. Sumitomo Dainippon Pharma
– Market share: 2%
– Sumitomo Dainippon Pharma has been investing in mRNA vaccine technology, aiming to address the evolving healthcare needs in Japan. Their vaccines have shown promising results, attracting interest from both local and international markets.
Insights:
The emergence of these top 10 mRNA vaccine firms in Japan signifies the country’s strong position in the global pharmaceutical industry. With a growing demand for mRNA vaccines, these firms are expected to play a crucial role in meeting the vaccination needs of the population. As Japan continues to invest in healthcare infrastructure and innovation, the market for mRNA vaccines is projected to expand further. By leveraging their expertise and resources, these firms are well-positioned to drive innovation and make a significant impact on public health in Japan and beyond.
Related Analysis: View Previous Industry Report
